KHN922 injection phase 1/2 solid tumor trial
Summary
ClinicalTrials.gov posted a new clinical trial registration for KHN922 injection, a Phase 1/2 study evaluating the treatment in patients with solid tumors. The trial is registered as NCT07514975 and includes study design details such as eligibility criteria and outcome measures. This registration fulfills requirements for publicly listing clinical trials conducted under FDA oversight.
What changed
A new clinical trial registration for KHN922 injection was posted to ClinicalTrials.gov. The study is a Phase 1/2 trial targeting solid tumor patients, with registration number NCT07514975. The posting includes standard ClinicalTrials.gov elements such as study design, participant eligibility, and planned outcome measures.
Pharmaceutical companies, clinical investigators, and healthcare providers involved in oncology research should note this new trial registration. Sponsors conducting FDA-regulated clinical trials are required to register and report results on ClinicalTrials.gov under federal law. This registration provides transparency into the drug development pipeline for KHN922 in solid tumor indications.
What to do next
- Monitor trial status and results for updates on ClinicalTrials.gov
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NLM.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.